Endoscopy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The endoscopy devices market size is projected to expand from USD 40.10 billion in 2025 and USD 42.73 billion in 2026 to USD 58.71 billion by 2031, registering a CAGR of 6.56% between 2026 to 2031. This report is Segmented by Device Type (Endoscopes [Rigid Endoscopes, and More], Endoscopic Operative Devices [Access Devices, and More], and More), Application (Gastrointestinal, and More), Usability (Reprocessed / Reusable Devices, and More), End-User (Hospitals, Academic Medical Centers, and More) and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Endoscopy Devices Market Trends and Insights

Rising Global Incidence of Gastrointestinal & Colorectal Cancers Driving Screening Demand

Colorectal cancer cases among U.S. adults aged 20-49 increased 9% between 2020 and 2024, prompting payers to broaden screening eligibility to younger cohorts. Endoscopy fleets therefore require faster refresh cycles, with high-volume centers acquiring high-definition (HD) colonoscopes that better visualize flat or depressed lesions responsible for 30% of interval cancers. Japan and South Korea illustrate the effect of mandatory screening: per-capita endoscope utilization runs three to four times higher than in Western systems, demonstrating the procedure volume that emerging Chinese and Indian programs could unleash. The World Health Organization’s 2024 cancer outlook projects a 47% rise in global cancer incidence by 2040, spotlighting gastrointestinal malignancies as the largest absolute increase. Regulators are also tightening quality standards; updated ISO 13485 audits link device performance directly to documented cancer-detection rates, raising the entry hurdle for new vendors.

Widespread Shift Toward Minimally Invasive Procedures Across Surgical Specialties

Minimally invasive techniques now represent 72% of elective abdominal surgeries in the United States, up from 64% in 2020. Bariatric endoscopic sleeve gastroplasty volumes jumped 38% in 2024 as shortages of GLP-1 agonists steered patients from pharmacotherapy to procedural weight management. Orthopedic arthroscopy follows a similar trajectory, with 85% of U.S. meniscus repairs completed arthroscopically in 2024. Robotic bronchoscopy platforms such as Intuitive Surgical’s Ion, cleared in 2024, reached an 89% diagnostic yield for sub-2 cm lung nodules, underscoring how flexible-scope technology increasingly merges with robotics. This broad procedural pivot expands the endoscopy devices market well beyond gastroenterology, opening white-space opportunities for hybrid visualization systems that blend rigid-scope precision with flexible-scope reach.

High Capital & Lifecycle Maintenance Costs of Advanced Endoscopic Systems

A fully integrated 4K tower with AI software lists between USD 180,000 and USD 250,000, about 60% higher than standard-definition rigs - a hurdle for community hospitals and ASCs with thin margins. Automated endoscope reprocessors (AERs), mandated by FDA and CDC protocols, cost USD 40,000-75,000 apiece, while high-level disinfectants add USD 12-18 per scope cycle. Total annual ownership of a reusable colonoscope averages USD 2,800 when maintenance, servicing, and reprocessing are included. Disposable scopes eliminate reprocessing costs but introduce a USD 200-400 per-case expense, limiting viability to low-volume or high-infection-risk settings. Emerging-market budgets remain tight; typical Indian public hospitals earmark USD 25,000 per year for endoscopy equipment, adequate for only a single mid-tier flexible scope. Leasing models that bundle capital, maintenance, and consumables into per-procedure fees are growing in Europe but still cover less than 5% of installed systems.

Other drivers and restraints analyzed in the detailed report include:

• Continuous Innovation in Endoscopy Visualization Enhancing Clinical Outcomes
• Expansion of Ambulatory Surgical Centers Boosting Outpatient Endoscopy Volumes
• Persistent Infection-Control Challenges and Heightened Regulatory Scrutiny

Segment Analysis

Visualization equipment expanded at an 8.25% CAGR between 2026 and 2031, the fastest among all device categories. The segment’s momentum reflects hospital demand for 4K and AI-ready towers like Olympus’s EVIS X1 and Fujifilm’s ELUXEO 8000, both cleared in 2024, which cut adenoma miss rates by up to 14 percentage points. Endoscopes retained 38.55% of 2025 revenue, with flexible variants dominating gastroenterology and pulmonology. Capsule endoscopes, led by Medtronic’s PillCam, carved a niche in small-bowel imaging and Crohn’s disease surveillance. Robotic-compatible visualization, exemplified by Intuitive’s Ion bronchoscope, blends flexible reach with robotic precision, underpinning 89% diagnostic yields in peripheral lung biopsies.

Manual instruments such as snares and forceps are commoditizing as Asian suppliers exert price pressure, yet high-margin digital visualization suites offset the squeeze. Karl Storz’s IMAGE1 S 4K system supports nerve-sparing prostatectomy, demonstrating the clinical lift associated with ultra-high resolution. As a result, visualization commanded the largest slice of incremental revenue in the endoscopy devices market. Hybrid 4K/HD portfolios cater to budget-sensitive geographies where reimbursement remains inadequate for premium hardware, extending the replacement opportunity curve.

Gastrointestinal endoscopy held a commanding 55.53% share in 2025, driven by more than 19 million annual colonoscopies in the United States alone. Yet laparoscopy clocked the swiftest growth at an 8.85% CAGR through 2031 as robotic platforms reduced surgeon fatigue and enabled single-port appendectomies and cholecystectomies. Intuitive Surgical’s da Vinci SP, cleared for transoral applications in 2024, illustrates the convergence of rigid and flexible modalities under a robotic umbrella. Pulmonology accelerates too: the U.S. Preventive Services Task Force’s 2024 guidelines expanded lung-cancer screening eligibility, adding 6.4 million candidates and fueling adoption of robotic bronchoscopy systems.

ENT, urology, and gynecology procedures continue to benefit from HD imaging upgrades, while neurology endoscopy gains attention for hydrocephalus management via single-burr-hole techniques. Orthopedics remains mature but innovates through augmented-reality overlays that guide ligament reconstruction, a feature Smith & Nephew commercialized in its 4K arthroscopy suite in 2024. The breadth of clinical indications ultimately broadens the total addressable endoscopy devices market, insulating revenue streams from single-specialty slowdowns.

Complete Report Scope:

• By Device Type
  • Endoscopes
    • Rigid Endoscopes
    • Flexible Endoscopes
    • Capsule Endoscopes
    • Robotic-assisted Endoscopes
  • Endoscopic Operative Devices
    • Irrigation / Suction Systems
    • Access Devices
    • Wound Protectors
    • Insufflation Devices
    • Manual Instruments
  • Visualization Equipment
    • Endoscopic Cameras
    • SD Visualization Systems
    • HD / 4K Visualization Systems
• By Application
  • Gastrointestinal Endoscopy
  • Laparoscopy
  • Pulmonology / Bronchoscopy
  • ENT / Otolaryngology
  • Urology
  • Gynecology
  • Cardiology
  • Neurology
  • Orthopedics / Arthroscopy
• By Usability
  • Reprocessed / Reusable Devices
  • Single-use / Disposable Devices
• By End-User
  • Hospitals & Academic Medical Centers
  • Ambulatory Surgical Centers
  • Specialty Clinics
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

List of Companies Covered in this Report:

• Olympus
• Boston Scientific
• Medtronic
• FUJIFILM
• Karl Storz
• Stryker
• Johnson & Johnson (Ethicon Endo-Surgery)
• HOYA
• Conmed
• Richard Wolf
• Cook Group
• Smiths Group
• Intuitive Surgical
• Ambu
• Arthrex
• B. Braun
• Ackermann Instrumente
• STERIS
• Interscope Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support